Fresenius SE & Co. KGaA stock (DE0005785604): Upcoming dividend payout

Fresenius SE & Co. KGaA has scheduled a dividend payment of €1.05 per share for May 2026, offering a yield of 2.56%. The stock rose 0.54% amid DAX recovery hopes tied to US inflation data.

Fresenius SE & Co. KGaA, a leading global healthcare group, announced a dividend of €1.05 per share payable on May 27, 2026, with the ex-date on May 25, according to DivvyDiary as of May 2026. The payout represents a 2.56% yield. Separately, the stock gained 0.54% as part of a DAX recovery linked to US inflation data and Middle East tensions, per MarketScreener on May 10, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Fresenius SE & Co. KGaA
• Sector/industry: Healthcare
• Headquarters/country: Germany
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Dialysis products, infusion therapy, hospitals
• Home exchange/listing venue: Frankfurt (FRE)
• Trading currency: EUR

Fresenius SE & Co. KGaA: core business model

Fresenius SE & Co. KGaA operates as a diversified healthcare company focused on providing products and services for critically ill patients worldwide. Its business spans dialysis care, medical care, and healthcare products through key subsidiaries. The group serves millions of patients annually, with a strong emphasis on chronic conditions like kidney failure.

The company generates revenue primarily from its four main business segments: Fresenius Medical Care for dialysis services, Fresenius Kabi for infusion and clinical nutrition, Fresenius Helios for hospital operations, and Fresenius Vamed for healthcare infrastructure. This integrated model allows Fresenius to cover the full spectrum from manufacturing to patient care, enhancing its global footprint.

Main revenue and product drivers for Fresenius SE & Co. KGaA

Dialysis products and services remain the largest revenue contributor, driven by Fresenius Medical Care, which operates thousands of clinics globally. Infusion therapies and generics from Fresenius Kabi target hospital and outpatient settings, benefiting from rising demand for cost-effective treatments. Hospital operations via Helios provide acute care in Europe, capitalizing on aging populations.

Key growth drivers include expanding dialysis capacity in emerging markets and innovation in biosimilars. For US investors, Fresenius Medical Care's NASDAQ listing (FMS) offers direct exposure to the US dialysis market, which accounts for a significant portion of group revenue.

Industry trends and competitive position

The global healthcare sector faces trends like digital health integration, rising chronic disease prevalence, and cost pressures from payers. Fresenius holds a leading position in dialysis with over one-third market share worldwide, bolstered by its vertical integration. Competitors include Baxter and B. Braun, but Fresenius' scale provides advantages in R&D and procurement.

Why Fresenius SE & Co. KGaA matters for US investors

US investors gain exposure to Fresenius via the Fresenius Medical Care ADR on NASDAQ, which represents substantial US operations amid a $100+ billion dialysis market. The group's ties to US healthcare spending, influenced by Medicare policies, make it relevant. Dividend payouts in EUR offer yield plays with currency diversification.

Conclusion

The upcoming dividend and recent stock gains highlight Fresenius SE & Co. KGaA's appeal as a steady healthcare dividend payer. With robust operations across key segments and relevance to US markets via its NASDAQ-listed unit, the company remains a notable name. Investors track upcoming earnings and macroeconomic factors like US inflation for further direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.